RFL-WT: the cash flow

Cash Flow Overview

Change in Cash

$50,094K

Free Cash flow

-$18,928K

Unit: Thousand (K) dollars

Positive Cash Flow Breakdown

Negative Cash Flow Breakdown

Cash Flow

2025-07-31

Loss (gain) on sale of property and equipment

-81

Amortization of discount on available-for-sale securities

-285

Unrealized loss (gain) on equity investments - cyclo

-5,144

Change in deferred income taxes

-165

Stock-based compensation

2,123

Gain on dtlm sale transactions

Trade accounts receivable

151

Interest receivable

-515

Inventory

Prepaid expenses and other current assets

-818

Prepaid clinical costs (current and non-current)

-112

Other receivables

273

Other assets

-28

Accounts payable and accrued expenses

-922

Other current liabilities

-67

Due to related parties

-10

Accrued expenses, noncurrent

913

Convertible notes payable

Other liabilities

Consolidated net loss

-30,643

Depreciation and amortization

288

Loss on impairment of goodwill

3,050

Realized gain on available-for-sale securities

178

Unrealized loss (gain) on convertible notes receivable, due from cyclo

-719

Net unrealized gain on investments - hedge funds

Realized loss on investment in equity securities

Loss on initial investment in day three upon acquisition

Realized gain on equity investments - cyclo

Recovery of receivables from cornerstone

In-process research and development expense

Gain on dissolution of a business

Equity in loss of day three

Credit loss expense

Net cash used in operating activities

-18,924

Purchase of property and equipment

Proceeds from sale of property and equipment

Purchases of available-for-sale securities

16,988

Proceeds from the sale and maturities of available-for-sale securities

80,694

Purchase of intangible assets

Payments for convertible notes receivable, due from cyclo

19,500

Cash paid in cyclo merger, net of cash acquired

2,709

Proceeds from hedge funds

2,547

Proceeds from day three patent sale

Proceeds from sales of equity securities

Issuance of convertible notes receivable, due from cyclo

Purchase of investments in cyclo

Issuance of convertible note receivable

Issuance of day three promissory notes

Proceeds from investments - other pharmaceuticals

Cash acquired in acquisition of day three, net of cash payments

Cash acquired in the cornerstone acquisition, net of cash payments

Net cash provided by (used in) investing activities

44,035

Payments for taxes related to shares withheld for employee taxes

215

Proceeds from issuance of common stock in rights offering, net of transaction costs

25,001

Proceeds from sale of rafael medical devices membership units

Principal payments on installment note payable

Purchases of treasury stock

Net cash provided by (used in) financing activities

24,830

Effect of exchange rate changes on cash and cash equivalents

153

Net increase (decrease) in cash and cash equivalents

50,094

Cash and cash equivalents at beginning of period

2,675

Cash and cash equivalents at end of period

52,769

Time Plot

Show the time plot by selecting a row from the table.